Revolution Medicines, Inc. (RVMD)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow RVMD in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on RVMD and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
RVMD at a glance
Key statistics
$42.13B
Market capitalization
- Previous close
- $196.55
- Open
- $197.79
- Day range
- $195.71 – $203.29
- Volume
- 1.11M
- Average volume (30 sessions)
- 2.20M
- Shares outstanding
- 214.34M
- Earnings per share
- $(8.25)
- Price / book
- 16.2
- Beta (1 year, vs SPY)
- 1.19
Where the price sits in its year
52-week range
84% of the range
- Below the 52-week high
- -12.2%
- Above the 52-week low
- +275.1%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day average, above its 200-day
- 20-day average
- $196.39+0.1%
- 50-day average
- $202.45-2.9%
- 200-day average
- $152.72+28.7%
Between the conventional 30 and 70 bands.
+4.3%
1 week
+2.0%
1 month
+7.4%
3 months
+146.8%
Year to date
+263.3%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with RVMD
RVMD on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on RVMD.
See the plans →
Every planScreen names like RVMD
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on RVMD
Put RVMD on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on RVMD
See whether there is an open premium alert on RVMD, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
RVMD headlines
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
GlobeNewswire Inc. · Sep 2, 2026
- U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
GlobeNewswire Inc. · Aug 26, 2026
- Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
GlobeNewswire Inc. · Jun 24, 2026
- Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
GlobeNewswire Inc. · May 31, 2026
- Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
Benzinga · May 15, 2026
- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
GlobeNewswire Inc. · May 6, 2026
- Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
GlobeNewswire Inc. · Apr 19, 2026
SEC Form 4, most recent first
Insider filings
Sandler Alan B.
−6.0K
Chief Development Officer · Option exercise
· Sep 29, 2026
Sandler Alan B.
−301
Chief Development Officer · Open-market sale
$61.62K · Sep 29, 2026
Sandler Alan B.
−2.2K
Chief Development Officer · Open-market sale
$441.80K · Sep 29, 2026
Sandler Alan B.
−1.0K
Chief Development Officer · Open-market sale
$202.81K · Sep 29, 2026
Sandler Alan B.
+6.0K
Chief Development Officer · Option exercise
$353.04K · Sep 29, 2026
Sandler Alan B.
−1.6K
Chief Development Officer · Open-market sale
$324.57K · Sep 29, 2026
Sandler Alan B.
−1.2K
Chief Development Officer · Open-market sale
$244.48K · Sep 29, 2026
Cislini Jeff
−765
SVP & General Counsel · Open-market sale
$158.60K · Sep 25, 2026
About Revolution Medicines, Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- Redwood City, CA
- Employees
- 883
- Listed since
- Feb 13, 2020
- Website
- revmed.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.